StockData
Vor Biopharma Inc. logo

Vor Biopharma Inc. (VOR) stock

VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 5/30
$18.18−0.79 (-4.16%)

Close on Nov 17, 2026Market cap $1.12BP/E –Yield –

Vor Biopharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Vor Biopharma's operating cash flow for the twelve months ending Sep 30, 2026 was -$119.17M. For fiscal 2025 it was -$142.71M. The highest annual figure on record is -$36.29M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$142.71M–
FY2024Dec 31, 2024-$99.66M–
FY2023Dec 31, 2023-$100.29M–
FY2022Dec 31, 2022-$85.14M–
FY2021Dec 31, 2021-$69.14M–
FY2020Dec 31, 2020-$36.29M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$32.75M–
Q2 FY2026Jun 30, 2026-$25.38M–
Q1 FY2026Mar 31, 2026-$38.25M–
Q4 FY2025Dec 31, 2025-$22.80M–
Q3 FY2025Sep 30, 2025-$53.66M–
Q2 FY2025Jun 30, 2025-$35.18M–
Q1 FY2025Mar 31, 2025-$31.07M–
Q4 FY2024Dec 31, 2024-$24.06M–
Q3 FY2024Sep 30, 2024-$23.29M–
Q2 FY2024Jun 30, 2024-$21.85M–
Q1 FY2024Mar 31, 2024-$30.47M–
Q4 FY2023Dec 31, 2023-$24.03M–
Q3 FY2023Sep 30, 2023-$27.90M–
Q2 FY2023Jun 30, 2023-$24.10M–
Q1 FY2023Mar 31, 2023-$24.27M–
Q4 FY2022Dec 31, 2022-$18.35M–
Q3 FY2022Sep 30, 2022-$18.90M–
Q2 FY2022Jun 30, 2022-$24.99M–
Q1 FY2022Mar 31, 2022-$22.90M–
Q4 FY2021Dec 31, 2021-$17.59M–
Q3 FY2021Sep 30, 2021-$17.34M–
Q2 FY2021Jun 30, 2021-$16.57M–
Q1 FY2021Mar 31, 2021-$17.65M–
Q4 FY2020Dec 31, 2020-$13.63M–
Q3 FY2020Sep 30, 2020-$8.25M–
Q2 FY2020Jun 30, 2020-$8.33M–
Q1 FY2020Mar 31, 2020-$6.09M–

More Vor Biopharma figures

See a number that looks wrong?